Dresbuxelimab Biosimilar Monoclonal Antibody (CD73) for Research
Pre-Made Dresbuxelimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-660-1mg | 1mg | 3090 |
| GMP-Bios-ab-660-10mg | 10mg | |
| GMP-Bios-ab-660-100mg | 100mg | |
| GMP-Bios-ab-660-xmg | >100mg |
Product Details
| Products Name (INN Index) | Pre-Made Dresbuxelimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody |
| INN Name | Dresbuxelimab |
| Target | CD73 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Akeso Biopharma |
| Conditions Approved | na |
| Conditions Active | COVID-19 |
| Conditions Discontinued | na |
| Development Tech | na |
About target - NT5E
1. Protein 5'-nucleotidase
2. Gene NT5E
3. Organism Homo sapiens (Human)
Function
Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
Catalytic activity
a ribonucleoside 5'-phosphate + H2O = a ribonucleoside + phosphate
EC:3.1.3.5
Source: Rhea.
Cofactor
Zn2+

